Compare BOTJ & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOTJ | EQ |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 57.8M |
| IPO Year | N/A | 2018 |
| Metric | BOTJ | EQ |
|---|---|---|
| Price | $17.80 | $0.85 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 4.0K | ★ 433.6K |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $47,669,000.00 | $4,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.22 | ★ N/A |
| Revenue Growth | ★ 8.53 | N/A |
| 52 Week Low | $11.56 | $0.27 |
| 52 Week High | $18.50 | $2.35 |
| Indicator | BOTJ | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 60.66 | 35.50 |
| Support Level | $17.50 | $0.81 |
| Resistance Level | $18.04 | $0.92 |
| Average True Range (ATR) | 0.62 | 0.10 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 65.09 | 10.98 |
Bank of the James Financial Group Inc is a bank holding company that provides retail and commercial banking, deposit services, lending services, mortgage brokerage services, and other banking services. The company provides a range of deposit services including checking accounts, savings accounts and other time deposits of various types, ranging from daily money market accounts to longer-term certificates of deposit. It offers various types of secured and unsecured consumer loans, including personal loans, lines of credit, overdraft lines of credit, automobile loans, installment loans, demand loans, and home equity loans. It operates three business segments community banking; mortgage banking, and investment advisory services.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.